Home › Triple-Negative Breast Cancer › Kentucky
Pag-aaral pangklinika para sa Triple-Negative Breast Cancer sa Kentucky
6 pag-aaral para sa Triple-Negative Breast Cancer ang naghahanap ng mga kalahok sa mga site sa Kentucky.
Mga Lungsod sa Kentucky
Opisyal na teksto ng pag-aaral (English)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044), Edgewood
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06393374Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Norton Healthcare, Inc., Louisville
- Mercy Health, Paducah
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT05846789Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Baptist Health Clinical Research, Elizabethtown
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 27, 2022 · NCT05037825Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.